Clinical Trial Update: Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer [Phase 2]

View source ↗

Summary

The update notes the completion of the Phase 2 CAPRI trial evaluating the combination of AZD6738 (ceralasertib) and olaparib in recurrent high-grade serous ovar…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• High-grade Serous Ovarian Cancer

Drugs mentioned

• AZD6738 (ceralasertib)
• Lynparza (olaparib)

Snippet

Sponsor: University of Pennsylvania | Conditions: High Grade Serous Carcinoma | Phase 2 | Status: COMPLETED